Beam Therapeutics Announces Pricing of Underwritten Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Jones Trading Upgrades Beam Therapeutics Inc (BEAM) to Buy
March 10, 2025 12:59 PM EDTJones Trading analyst Soumit Roy upgraded Beam Therapeutics Inc (NASDAQ: BEAM) from Hold to Buy with a price target of $34.00.
The analyst comments "Model changes: We are raising our POS for AATD to 35% from 15%, increasing our adjusted peak sales to ~$1.9BN in 2036, upgrading our rating to Buy from Hold and a PT of $34. BEAM's in vivo edited AATD data mark an important step for the gene editing space, where effective editing levels were observed. Liver biopsy data in the future would accurately quantify the percent editing, but management mentioned that likely >50%... More
